| 
October 5, 2015 Guideline Summaries American Gastroenterological Association Institute National Institute for Health and Care Excellence (NICE) The Endocrine Society |
Announcements Conference News - The Guidelines International Network (G-I-N) 12th annual conference will take place from October 7–10, 2015 in Amsterdam. The theme is "Engaging all stakeholders. Guidelines from a societal perspective." To register and book a pre-conference course, visit the G-I-N Conference Web site.
- Registration is now open for the Agency for Healthcare Research and Quality (AHRQ) 2015 Research Conference. It will be held October 4–6 at the Crystal Gateway Marriott Hotel and Convention Center in Crystal City, VA. The conference is titled "Producing Evidence and Engaging Partners to Improve Health Care." The latest version of the agenda is now available, including an updated list of speakers. Explore sessions and begin to plan your participation in the meeting. Visit the conference home page for more information.
- The Guidelines International Network North America (G-I-N NA) continues to sponsor a monthly webinar series on topics of interest to the North American guideline community. Information on upcoming webinars, as well as audio files and slides from past webinars, is available on the G-I-N Web site.
U.S. Food and Drug Administration (FDA) Advisories - September 21, 2015: Tramadol: Drug Safety Communication - FDA Evaluating Risks of Using in Children Aged 17 and Younger: FDA is investigating the use of the pain medicine tramadol in children aged 17 years and younger, because of the rare but serious risk of slowed or difficult breathing. This risk may be increased in children treated with tramadol for pain after surgery to remove their tonsils and/or adenoids. FDA is evaluating all available information and will communicate final conclusions and recommendations to the public when the review is complete.
- September 22, 2015: Avycaz (ceftazidime and avibactam): Drug Safety Communication - Dose Confusion and Medication Errors: FDA is warning health care professionals about the risk for dosing errors with the intravenous antibacterial drug Avycaz (ceftazidime and avibactam) due to confusion about the drug strength displayed on the vial and carton labels. Avycaz was initially approved with the vial and carton labels displaying the individual strengths of the two active ingredients (i.e., 2 gram/0.5 gram); however, the product is dosed based on the sum of the active ingredients (i.e., 2.5 gram). To prevent medication errors, FDA revised the labels to indicate that each vial contains Avycaz 2.5 gram, equivalent to ceftazidime 2 gram and avibactam 0.5 gram.
Health Awareness Topics - October 2015 How to Participate - Submit Guidelines: Visit our Submit Guidelines page for information on how to submit your organization's guidelines.
- Suggest a Guideline for Possible Inclusion: Submit your suggestions for evidence-based clinical practice guidelines that you would like to see included in NGC.
- Suggest a Guideline Synthesis Topic: We welcome your suggestions for guideline synthesis topics!
NGC's Sister Resource Look for Quality Measures in AHRQ's National Quality Measures Clearinghouse (NQMC).
| This email was sent to rssproject471@gmail.com using GovDelivery, on behalf of: Agency for Healthcare Research and Quality (AHRQ) · 540 Gaither Road · Rockville, MD 20850 · 301-427-1364 | |
Belum ada tanggapan untuk "NGC Update Service: October 5, 2015"
Post a Comment